{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:04:10Z","timestamp":1760123050188,"version":"3.37.3"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Up-to-date information on the current progress made in the research and development to control the global COVID-19 pandemic is important. The study aimed to analyze the clinical trial characteristics and vaccine development progress of the new Coronavirus Disease 2019 (COVID-19) registered with the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP).<\/jats:p>\n            <jats:p>A comprehensive search of COVID-19 clinical trials since the establishment of the ICTRP to June 11, 2020, was conducted to record and analyze relevant characteristics. Chi-Squared test was used to compare the statistical differences between different research types, interventions, and sources.<\/jats:p>\n            <jats:p>A total of 3282 COVID-19 clinical trials in 17 clinical trial registration centers were registered with the WHO ICTRP. The main research sources for the present study were ClinicalTrials.gov and ChiCTR. There were significant differences in the parameters of study location (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000), number of participants (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000), study duration (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001), research stage (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000), randomization procedure (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000), and blinding method (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000) between the 2 registration sources. There were significant differences in all the parameters between different kinds of intervention methods. Hydroxychloroquine, plasma therapy, and Xiyanping injection were the high-frequency research drugs used. Ten different vaccine studies were registered under phases I-II.<\/jats:p>\n            <jats:p>Amongst the studies researched, heterogeneity existed for various parameters. Differences in the type of study, interventions, and registration sources of the studies led to significant differences in certain parameters of the COVID-19 clinical trials. The statistics of high-frequency drugs and the progress of vaccine trials may provide an informative reference for the prevention and control of COVID-19.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022840","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T01:04:06Z","timestamp":1603501446000},"page":"e22840","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-8791","authenticated-orcid":false,"given":"Gao","family":"Song","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Pu\u2019er People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng Qun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, The Pu\u2019er People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian Wen","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Puer People's Hospital, Yunnan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s13280-016-0809-2","article-title":"Economic growth, urbanization, globalization, and the risks of emerging infectious diseases in China: a review","volume":"46","author":"Wu","year":"2017","journal-title":"Ambio"},{"key":"R2-20230916","first-page":"426","article-title":"Several emergency and re-emerging infectious diseases","volume":"33","author":"Xu","year":"2018","journal-title":"Chinese J of Pra Ped"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome- related coronavirus: classifying 2019- nCoV and naming it SARS- CoV-2","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"key":"R6-20230916","first-page":"401","article-title":"Data sharing statements for clinical trials","volume":"114","author":"Taichman","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"R7-20230916","first-page":"1","article-title":"A Review of Ginseng Clinical Trials Registered in the WHO International Clinical Trials Registry Platform","volume":"2018","author":"Yingchun","year":"2018","journal-title":"BioMed Research International"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/jebm.12248","article-title":"Iranian clinical trials: an analysis of registered trials in International Clinical Trial Registry Platform (ICTRP)","volume":"10","author":"Feizabadi","year":"2017","journal-title":"J Evid Based Med"},{"key":"R9-20230916","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3203-0","article-title":"Design and implementation of a large and complex trial in emergency medical services","volume":"20","author":"Robinson","year":"2019","journal-title":"Trials"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12883-017-0809-2","article-title":"Evaluation and implementation of highly challenging balance training in clinical practice for people with Parkinson's disease: protocol for the HiBalance effectiveness-implementation trial","volume":"17","author":"Leavy","year":"2017","journal-title":"BMC Neurol"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s13365-015-0415-2","article-title":"International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271","volume":"22","author":"Robertson","year":"2016","journal-title":"J of NeuroVir"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jebm.12203","article-title":"Characteristics of anticancer drug studies registered on the Chinese Clinical Trial Registry (ChiCTR) from 2007 to 2015","volume":"9","author":"Song","year":"2016","journal-title":"J Evid Based Med"},{"key":"R13-20230916","article-title":"Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005","author":"Magdalena","year":"2018","journal-title":"BMJ"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"e13062","DOI":"10.1097\/MD.0000000000013062","article-title":"Improve the ethical review of clinical trials on traditional medicine: a cross-sectional study of clinical trial registration, ethical review, and informed consent in clinical trials of Traditional Chinese Medicine","volume":"97","author":"Zhao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2019.01.001","article-title":"Innovation in oncology clinical trial design","volume":"74","author":"Verweij","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"e024900","DOI":"10.1136\/bmjopen-2018-024900","article-title":"Clinical features, management and outcomes of severe ischaemic stroke in tertiary hospitals in China: protocol for a prospective multicentre registry-based observational study","volume":"8","author":"Simiao","year":"2018","journal-title":"BMJ Open"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"e018320","DOI":"10.1136\/bmjopen-2017-018320","article-title":"Adaptive design clinical trials: a review of the literature and clinical trials.gov","volume":"8","author":"Bothwell","year":"2018","journal-title":"BMJ Open"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless Phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clinical Trials"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"e00399","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20230916","first-page":"1","article-title":"Progress of new coronavirus (2019-nCoV) therapeutic drugs in vivo and in vitro and research and development of drugs","author":"Song","year":"2020","journal-title":"JVirol"},{"key":"R21-20230916","first-page":"1","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Research"},{"key":"R23-20230916","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis published online ahead of print, 2020 May 22 retracted in: Lancet. null","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jinf.2019.11.024","article-title":"Specificity, Kinetics and Longevity of Antibody Responses to Avian Influenza A(H7N9) Virus Infection in Humans","volume":"80","author":"Chen","year":"2020","journal-title":"J Infect"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jinf.2016.02.011","article-title":"Zika fever and congenital Zika syndrome: an unexpected emerging arboviral disease","volume":"72","author":"Chan","year":"2016","journal-title":"J Infect"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg Infectious Dis"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JRS-201017","article-title":"Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19","volume":"31","author":"Alzoughool","year":"2020","journal-title":"Int J Risk Saf Med"},{"key":"R29-20230916","first-page":"1","article-title":"Application and research progress of Chinese medicine in the prevention and treatment of new coronary pneumonia","volume":"34","author":"Chen","year":"2020","journal-title":"JShanghai Univers Traditi Chin Med"},{"key":"R30-20230916","first-page":"1045","article-title":"Meta-analysis of the efficacy and safety of Lianhua Qingwen combined with Western medicine in the treatment of common patients with new coronary pneumonia","volume":"26","author":"Zhang","year":"2020","journal-title":"J Hainan Med Coll"},{"key":"R31-20230916","first-page":"1045","article-title":"Meta-analysis of the efficacy and safety of Lianhua Qingwen combined with Western medicine in the treatment of common patients with new coronary pneumonia","volume":"26","author":"Wenbin","year":"2020","journal-title":"J Hainan Med Coll"},{"key":"R32-20230916","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr Trop Med Rep"},{"key":"R33-20230916","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"R34-20230916","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J Microbiol Biotechnol"},{"key":"R35-20230916","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","article-title":"Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine","volume":"12","author":"Lin","year":"2007","journal-title":"Antivir Ther"},{"key":"R36-20230916","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"R37-20230916","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.vaccine.2016.03.104","article-title":"MERS-CoV vaccine candidates in development: the current landscape","volume":"34","author":"Modjarrad","year":"2016","journal-title":"Vaccine"},{"key":"R38-20230916","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.vaccine.2005.01.036","article-title":"The development of vaccines against SARS corona virus in mice and SCID-PBL\/hu mice","volume":"23","author":"Okada","year":"2005","journal-title":"Vaccine"},{"key":"R39-20230916","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/infdis\/jiaa152","article-title":"Human challenge studies to accelerate coronavirus vaccine licensure","volume":"221","author":"Eyal","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T03:48:26Z","timestamp":1694836106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":36,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022840","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}